Mesh Bio addresses chronic metabolic diseases within Asia
London-based MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup in Singapore, have announced their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. The partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies. Mesh will collaborate with its network of healthcare provider customers to recruit patients for the study. MultiOmic will generate genomic, proteomic, metabolomic and potentially other omics data from anonymized body fluid samples.